Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05465174 |
|
Recruitment Status :
Recruiting
First Posted : July 19, 2022
Last Update Posted : March 29, 2024
|
Sponsor:
Sabine Mueller, MD, PhD
Collaborators:
Bristol-Myers Squibb
Day One Biopharmaceuticals, Inc.
Information provided by (Responsible Party):
Sabine Mueller, MD, PhD, University of California, San Francisco
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 1, 2027 |
| Estimated Study Completion Date : | March 1, 2028 |